<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349425</url>
  </required_header>
  <id_info>
    <org_study_id>7264-010</org_study_id>
    <secondary_id>AF219-010</secondary_id>
    <nct_id>NCT02349425</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough</brief_title>
  <official_title>A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects With Refractory Chronic Cough</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afferent Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afferent Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, crossover, dose escalation study of
      gefapixant (AF-219) in subjects with Refractory Chronic Cough.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2015</start_date>
  <completion_date type="Actual">February 9, 2016</completion_date>
  <primary_completion_date type="Actual">February 1, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in cough frequency</measure>
    <time_frame>2 weeks</time_frame>
    <description>objective cough monitoring - 24 hour sound recordings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduce subjective scores of cough severity</measure>
    <time_frame>2 weeks</time_frame>
    <description>completion of daily cough severity diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improve cough-specific quality of life</measure>
    <time_frame>2 weeks</time_frame>
    <description>completion of Leicester Cough Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Refractory Chronic Cough</condition>
  <arm_group>
    <arm_group_label>Gefapixant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefapixant 50 mg tablets administered by mouth twice daily for 16 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match gefapixant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets administered by mouth twice daily for 16 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefapixant</intervention_name>
    <arm_group_label>Gefapixant</arm_group_label>
    <arm_group_label>Placebo to match gefapixant</arm_group_label>
    <other_name>AF-219</other_name>
    <other_name>MK-7264</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for gefapixant)</intervention_name>
    <arm_group_label>Gefapixant</arm_group_label>
    <arm_group_label>Placebo to match gefapixant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chest radiograph or CT thorax within the last 12 months not demonstrating any
             abnormality considered to be significantly contributing to the chronic cough

          -  Refractory chronic cough for at least one year: a cough that is unresponsive to at
             least 8 weeks of targeted treatment for identified underlying triggers including
             reflux disease, asthma and post-nasal drip or unexplained cough: a cough for which no
             objective evidence of an underlying trigger can be determined after investigation

          -  Score of ≥ 40mm on the Cough Severity VAS at Screening

          -  Women of child-bearing potential must use 2 forms of acceptable birth control method
             from Screening through the Follow-Up Visit.

          -  Male subjects and their partners of child-bearing potential must use 2 methods of
             acceptable birth control from Screening until 3 months after the last dose of study
             drug.

          -  Written informed consent.

          -  Willing and able to comply with all aspects of the protocol.

        Exclusion Criteria:

          -  Current smoker

          -  Individuals who have given up smoking within the past 6 months, or those with &gt;20
             pack-year smoking history

          -  Treatment with an ACE-inhibitor as the potential cause of a subject's cough, or
             requiring treatment with an ACE-inhibitor during the study or within 4 weeks prior to
             the Baseline Visit (Day 0)

          -  FEV1/FVC &lt; 60%

          -  History of upper respiratory tract infection or recent significant change in pulmonary
             status within 4 weeks of the Baseline Visit (Day 0)

          -  History of opioid use within 1 week of the Baseline Visit (Day 0)

          -  Requiring concomitant therapy with prohibited medications

          -  Body mass index (BMI) &lt;18 kg/m2 or ≥ 37 kg/m2

          -  History of concurrent malignancy or recurrence of malignancy within 2 years prior to
             Screening (not including subjects with &lt;3 excised basal cell carcinomas)

          -  History of a diagnosis of drug or alcohol dependency or abuse within approximately the
             last 3 years

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, gastroplasty, any
             type of bariatric surgery, vagotomy, or bowel resection)

          -  Screening systolic blood pressure (SBP) &gt;160 mm Hg or a diastolic blood pressure (DBP)
             &gt;90 mm Hg

          -  Clinically significant abnormal electrocardiogram (ECG) at Screening

          -  Personal or family history of congenital long QT syndrome or family history of sudden
             death

          -  Cardiac pacemaker

          -  Significantly abnormal laboratory tests at Screening

          -  Breastfeeding

          -  Treatment with an investigational drug (except gefapixant) or biologic within 60 days
             preceding the first dose of study medication or plans to take another investigational
             drug or biologic within 30 days of study completion

          -  Blood donation within 56 days or plasma donation within 7 days prior to dosing

          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with trial participation or
             investigational product administration or may interfere with the interpretation of
             trial results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kitt, MD</last_name>
    <role>Study Director</role>
    <affiliation>Afferent Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://dx.doi.org/10.1016/S0140-6736(14)61255-1</url>
    <description>P2X3 Receptor Antagonist (AF-219) in Refractory Chronic Cough: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Study</description>
  </link>
  <reference>
    <citation>Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, Smith JA. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2015 Mar 28;385(9974):1198-205. doi: 10.1016/S0140-6736(14)61255-1. Epub 2014 Nov 25.</citation>
    <PMID>25467586</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

